In honor of #WomensEqualityDay in the U.S., we celebrate the incredible achievements of women and their vital contributions to the patients we serve. We are proud to have a team of inspiring female leaders at Zymeworks who drive our mission to develop innovative biotherapeutics for difficult-to-treat cancers and other serious diseases. At Zymeworks, diversity, equity, and inclusion are at the heart of everything we do. We are committed to supporting and empowering individuals from all backgrounds, ensuring that our leadership and workforce reflect the richness of our global community. Laura O'Connor
Zymeworks Inc.
Biotechnology Research
Vancouver, BC 26,857 followers
Developing novel medicines for patients with difficult-to-treat cancers and other serious diseases.
About us
Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers. A Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for zanidatamab as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC) has been accepted and granted Priority Review. A BLA has also been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. If approved, zanidatamab would be the first HER2-targeted treatment specifically approved for BTC in the U.S. and China. Zymeworks is rapidly advancing a deep pipeline of product candidates based on its experience and capabilities in both antibody-drug conjugates and multispecific antibodies. In addition to Zymeworks’ wholly owned pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies.
- Website
-
http://www.zymeworks.com
External link for Zymeworks Inc.
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Vancouver, BC
- Type
- Public Company
- Founded
- 2003
- Specialties
- antibody therapeutics, bispecific antibodies, effector function modulation, ADC, Breast Cancer, Gastric Cancer, protein engineering, Immune redirection, and Biliary Tract Cancer
Locations
-
Primary
114 E 4th Avenue
Suite 800
Vancouver, BC V5T1G4, CA
Employees at Zymeworks Inc.
-
Daniel Dex
Senior Vice President, Corporate Secretary and General Counsel at Zymeworks Inc.
-
Michelle Seltenrich
Director, FP&A
-
Derek Miller
Life sciences executive, board member, consultant and mentor with a successful track record of 25+ years across Corporate Development, Business…
-
Carlos Campoy
Board Director | Retired Public Company CFO | Audit Committee Chair | Global Business Perspective | Strategic Business Partner | Life Sciences Leader…
Updates
-
We’re searching for an individual to join our team as the Director of Medical Writing. In this role, the individual will work with our research scientists to outline, write and coordinate review and editing of medical writing deliverables, prepare edits and finalize documents primarily related to INDs, early and late phase clinical #oncology research. This role can be based out of our following offices: Redwood City, CA, Vancouver, BC, Bellevue, WA, Singapore, and Dublin. Learn more: https://lnkd.in/ezBz2ZaD #Zymeworks #Hiring #WeareHiring #Biotech #BiotechJobs #Opportunity #DrugDevelopment #DrugDiscovery #OpentoWork #GreatPlacetoWork #Careers #OncologyJobs #ADCtechnology #MultifunctionalTherapeutics #BiotechCareers #RedwoodJobs #VancouverJobs #DublinJobs #SingaporeJobs #MedicalWriting
-
-
At Zymeworks, we believe in the power of diversity and inclusivity. We are proud to share recent Pride events from our global hubs in Dublin, Redwood City, Singapore, Bellevue, and Vancouver, each showcasing unique celebrations and heartfelt messages of support for the #LGBTQ+ community. Join us in celebrating love, acceptance, and the vibrant diversity that makes us stronger. Together, we continue to build a workplace where everyone can bring their true selves to work every day. #PrideMonth #DiversityAndInclusion #LoveIsLove #ZymeworksPride #PrideInBiotech #PRIDE2024
-
Ready to drive innovation within the #biotech industry? Collaboration and innovation are part of everything we do at Zymeworks, and we are always seeking new professionals to join our scientific and corporate teams to help fuel our pipeline of potential. If you’re looking to advance your career and make a meaningful difference using your skills and talents, check out available opportunities: https://lnkd.in/eiyDybK3 #BiotechJobs #WeareHiring #OncologyJob #Scientist #PrincipalScientist #Immunology #ResearchAssociate #VancouverJobs #SanFranciscoJobs #ADCTechnology #Pharmacology
-
-
Our executive team will be attending and presenting at four conferences in September. Presentations and webcasts will be available on our website at: https://lnkd.in/gzFaAHj6 For details, see our press release: https://lnkd.in/esmjC5Cp
-
-
Our camptothecin payload is specifically designed for antibody-drug conjugate (ADC) use and is paired with established linker and conjugation technologies that provide a good balance of stability, safety, and anti-tumor activity. Michael Brant, Scientist, Medicinal Chemistry, will deliver a poster presentation at #ACSFall2024 today to discuss our novel camptothecin drug-linker platform engineered specifically for ADC application. Learn more about ACS Fall taking place August 18-22 in Denver, Colorado: https://lnkd.in/egqHcxCW
-
-
Ongoing innovations in antibody-drug conjugates (ADCs) are revolutionizing cancer treatment. Breakthroughs in linker-payload technologies and personalized medicine are enhancing therapeutic benefit and enabling treatments tailored to individual patients, providing new hope across various malignancies. Explore how advancements in ADCs are redefining cancer treatment and our unique approach to their design and development in this article from Drug Target Review: https://lnkd.in/ecVhiuqp Paul Moore Raffaele Colombo Jamie Rich #DrugDevelopment #ClinicalTrial #ADCs #AntibodyDrugConjugates #PersonalizedMedicine #Cancer #MultispecificTherapeutics #Oncology
-
-
We are proud to be a member of the Canada-ASEAN Business Council, an organization committed to enhancing trade, investment, and economic collaboration between Canada and the vibrant nations of the ASEAN region. With the launch of our Early R&D hub in Singapore last year, we are excited to continue forging new connections within the global #biotech community, leveraging the region's expertise and resources to make a meaningful impact on the lives of patients battling difficult-to-treat cancers and other serious diseases. Learn more about their work: https://lnkd.in/e5Aj4wkv #CanadaASEAN #Biotech #HealthcareInnovation #CancerResearch #GlobalHealth #LifeSciences #Singapore #ASEANBusiness #PatientCare #Innovation #EarlyResearch
-
-
Our team is advancing next-generation T cell engagers using the TriTCE Co-Stim platform, which integrates CD28 costimulation to potentially enhance anti-tumor activity. By addressing challenges such as efficacy against solid tumors and dose-limiting toxicities, we aim to explore improved treatment options for cancers with limited T cell infiltration and function. Learn more from our Chief Scientific Officer Paul Moore, PhD, and Director of Preclinical, Multispecific Antibody Therapeutics Nina E. Weisser, PhD, in an interview with Drug Discovery World: https://lnkd.in/e55maHmb #CancerResearch #Immunotherapy #TCellEngagers #AntibodyDrugConjugates #Oncology #NextGenTherapies #PrecisionMedicine #DrugDiscovery #CancerTreatment #Biotech #CancerTherapies #ClinicalResearch
-
-
During the Wedbush PacGrow Healthcare Conference, our management team will participate in a panel discussion on August 14 at 8:45am ET and will participate in one-on-one meetings on August 13-14 in New York. See our press release: https://lnkd.in/exJU9SaH
-